Prognostic value of plasma soluble CD40 ligand in patients with chronic non-valvular atrial fibrillation

Europace

Volumn 10, Issue 2, 2008, Pages 210-214

  Duygu, Hamza ^a   Barisik, Vatan ^b   Kurt, Huseyin ^b   Turk, Ugur ^c   Ercan, Ertugrul ^c   Kose, Sukran ^b  

^a Karsiyaka Devlet Hastanesi   (Turkey)

^b Tepecik Training and Research Hospital ^*  (Turkey)

^c Central Hospital Izmir   (Turkey)

Author keywords

Atrial fibrillation; Embolic event; Soluble CD40 ligand; Thrombus

Indexed keywords

CD40 LIGAND; ECHO CONTRAST MEDIUM;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; EMBOLISM; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HUMAN; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; THROMBOGENESIS; TRANSIENT ISCHEMIC ATTACK; AGED; BLOOD; CHRONIC DISEASE; COHORT ANALYSIS; CORONARY ARTERY THROMBOSIS; MIDDLE AGED; PHYSIOLOGY; PREDICTION AND FORECASTING; STROKE; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM;

AGED; ATRIAL FIBRILLATION; CD40 LIGAND; CHRONIC DISEASE; COHORT STUDIES; CORONARY THROMBOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STROKE; THROMBOEMBOLISM;

EID: 41949108677     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eum284     Document Type: Article

References (49)

1. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N.
2. Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death: the Framingham Heart Study. Circulation 1995;92:835-41.
3. Atrial fibrillation investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449- 57.
4. Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. reduce flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr 1999;12:1080-7.
5. Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke 2000;31:822-7.
6. Feinberg WM, Pearce LA, Hart RG, Cushman M, Cornell ES, Lip GY et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 1999;30:2547- 53.
7. Lip GY, Lip PL, Zarifis J, Watson RD, Bareford D, Lowe GD et al. Fibrin D-dimer and β-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low dose warfarin and aspirin. Circulation 1996;94:425-31.
8. Goette A, Ittenson A, Hoffmanns P, Reek S, Hartung W, Klein H et al. Increased expression of P-selectin in patients with chronic atrial fibrillation. Pacing Clin Electrophysiol 2000;23:1872-5.
9. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with non-valvular atrial fibrillation: relationship to stroke risk factors. Circulation 2002;106:1962-7.
10. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Prognostic value of plasma von Willebrand factor and soluble P-selection as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003;107:3141-5.
11. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006;27:136-49.
12. Marin F, Corral J, Roldan V, Gonzalez-Conejero R, del Rey ML, Sogorb F et al. Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. J Mol Cell Cardiol 2004;37:699-704.
13. Gawaz M, Neumann FJ, Dickfeld T, Koch W, Laugwitz KL, Adelsberger H et al. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 1998;98:1164-71.
14. Schonbeck U, Libby P. CD40 signalling and plaque instability. Circ Res 2001;89:1092-103.
15. Blann AD, Tan KT, Tayebjee MH, Davagnanam I, Moss M, Lip GY. Soluble CD40L in peripheral artery disease. Relationship with disease severity, platelet markers and the effects of angioplasty. Thromb Haemost 2005;93:578-83.
16. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002;106:896-9.
17. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporarily limited by coexpressed CD40. Blood 2001;98:1047-54.
18. Aukrust P, Müller F, Ueland T, Berget T, Aaser E, Brunsvig A et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999;100:614-20.
19. Cipollone F, Ferri C, Desideri G, Paloscia L, Materazzo G, Mascellanti M et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 2003;108:2776-82.
20. Gokulakrishnan K, Deepa R, Mohan V, Gross MD. Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome-the Chennai Urban Rural Epidemiology Study. Metabolism 2006;55:237-42.
21. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70.
22. Conway DS, Buggins P, Hughes E, Lip GY. Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. Am J Cardiol 2004;94:508-10.
23. Roldan V, Marin F, Blann AD, Garcia A, Marco P, Sogorb F et al. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J 2003;24:1373-80.
24. Kamath S, Chin BS, Blann AD, Lip GY. A study of platelet activation in paroxysmal, persistent and permanent atrial fibrillation. Blood Coagul Fibrinolysis 2002;13:627-36.
25. Iga K, Izumi C, Inoko M, Kitaguchi S, Himura Y, Gen H et al. Increased thrombin-antithrombin III complex during an episode of paroxysmal atrial fibrillation. Int J Cardiol 1998;66:153-6.
26. Li-Saw-Hee FL, Blann AD, Gurney D, Lip GY. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation: effects of cardioversion and return of left atrial function. Eur Heart J 2001;22:1741-7.
27. Marin F, Roldan V, Climent VE, Ibanez A, Garcia A, Marco P et al. Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. Heart 2004;90:1162-6.
28. Asinger RW, Koehler J, Pearce LA, Zabalgoitia M, Blackshear JL, Fenster PE et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: II. Dense spontaneous echocardiographic contrast. J Am Soc Echocardiogr 1999;12:1088-96.
29. Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 2004;148:462-6.
30. Thambidorai SK, Parakh K, Martin DO, Shah TK, Wazni O, Jasper SE et al. Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. Am J Cardiol 2004;94:805-7.
31. Pongratz G, Brandt-Pohlmann M, Henneke KH, Pohle C, Zink D, Gehling G et al. Platelet activation in embolic and preembolic status of patients with non rheumatic atrial fibrillation. Chest 1997;111:929-33.
32. Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 1997;29:106-12.
33. Conway DS, Heeringa J, Van Der Kuip DA, Chin BS, Hofman A, Witteman JC et al. Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study. Stroke 2003;34:413-7.
34. Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non rheumatic atrial fibrillation. Heart 1997;77:407-11.
35. Fukuchi M, Watanabe J, Kumagai K, Katori Y, Baba S, Fukuda K et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J Am Coll Cardiol 2001;37:1436-42.
36. Goldsmith I, Kumar P, Carter P, Blann AD, Patel RL, Lip GY. Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study. Am Heart J 2000;140:777-84.
37. von Hundelshausen P, Weber C. Platelets as immune cells bridging inflammation and cardiovascular disease. Circ Res 2007;100:27-40.
38. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-4.
39. André P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nature Med 2002;8:247-52.
40. Hollenbaugh D, Mischel-Petty N, Edwards CP, Simon JC, Denfeld RW, Kiener PA et al. Expression of functional CD40 by vascular endothelial cells. J Exp Med 1995;182:33-40.
41. Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 1995;155:4917-25.
42. Blann AD, Choudhury A, Freestone B, Patel J, Lip GY. Soluble CD40 ligand and atrial fibrillation: relationship to platelet activation, and endothelial damage/dysfunction. Int J Cardiol 2007; [Epub ahead of print].
43. Hammwöhner M, Ittenson A, Dierkes J, Bukowska A, Klein HU, Lendeckel U et al. Platelet expression of CD40/CD40 ligand and its relation to inflammatory markers and adhesion molecules in patients with atrial fibrillation. Exp Biol Med 2007;232:581-9.
44. Lip GY, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 2007;38:1229-37.
45. Chello M, Spadaccio C, Patti G, Lusini M, Barbato R, Goffredo C et al. Simvastatin reduces platelet-endocardium adhesion in atrial fibrillation. Atherosclerosis 2007; [Epub ahead of print].
46. Mackstaller LL, Alpert JS. Atrial fibrillation: a review of mechanism, etiology, and therapy. Clin Cardiol 1997;20:640-50.
47. Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, persistent dilemmas. Stroke 1988;19:937-41.
48. Odell JA, Blackshear JL, Davies E, Byrne WJ, Kollmorgen CF, Edwards WD et al. Thoracoscopic obliteration of the left atrial appendage: potential for stroke reduction. Ann Thorac Surg 1996;61:565-9.
49. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:651-745.